Integrate | $17,000,000 | (Feb 13, 2026)
daypass.com | $2,000,000 | (Feb 13, 2026)
CYDELPHI | $3,000,000 | (Feb 13, 2026)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Maestro Tech, Inc. | $1,200,000 | (Feb 13, 2026)
Ever | $31,000,000 | (Feb 13, 2026)
Manufact (formerly mcp-use) | $6,300,000 | (Feb 13, 2026)
Reflow | $15,000,000 | (Feb 13, 2026)
Santé(US) | $7,600,000 | (Feb 13, 2026)
Alva Energy | $33,000,000 | (Feb 13, 2026)
Project Omega | $12,000,000 | (Feb 13, 2026)
Brandlight | $30,000,000 | (Feb 12, 2026)
Inertia | $450,000,000 | (Feb 12, 2026)